PD-1 and PD-L1 in Cancer Immunotherapy
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: 30 June 2026 | Viewed by 58
Special Issue Editor
Special Issue Information
Dear Colleagues,
The PD-1/PD-L1 axis has emerged as a critical pathway in cancer immunotherapy, revolutionizing the treatment landscape for numerous malignancies. Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated remarkable clinical efficacy across a wide range of tumor types. However, significant challenges remain, including understanding the mechanisms of resistance, identifying predictive biomarkers, and optimizing combination therapies to enhance therapeutic outcomes.
This Special Issue aims to highlight cutting-edge research and advancements in the field of PD-1/PD-L1 immunotherapy. We welcome original research articles and reviews that explore the molecular mechanisms of PD-1/PD-L1 signaling, the development of novel therapeutic strategies, and the integration of single-cell and spatial omics technologies to unravel the complexities of tumor–immune interactions. Contributions addressing the clinical challenges of resistance, toxicity management, and patient stratification are also encouraged.
We look forward to receiving your contributions.
Dr. Aleksandar Obradovic
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PD-1
- PD-L1
- cancer immunotherapy
- immune checkpoint inhibitors
- resistance mechanisms
- combination therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
